Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Horse ATG + cyclosporine + romiplostim for untreated severe aplastic anemia (W-JHS AA03)
jRCTs071240082Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Jan 2025
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of antilymphocyte immunoglobulin (horse), cyclosporine and romiplostim in aplastic anemia, sponsored by Kyowa Kirin. Primary endpoint: Primary hematologic response at week 12. Started Jan 2025; status: recruiting.
02
Drugs
antilymphocyte immunoglobulin (horse)cyclosporineromiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on jRCTs071240082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071240082.